Analysts Offer Predictions for TNYA Q1 Earnings

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities research analysts at William Blair issued their Q1 2025 earnings per share (EPS) estimates for Tenaya Therapeutics in a research note issued on Monday, March 10th. William Blair analyst S. Corwin forecasts that the company will post earnings of ($0.15) per share for the quarter. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. William Blair also issued estimates for Tenaya Therapeutics’ Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.64) EPS.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its earnings results on Monday, March 17th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04.

Other analysts also recently issued research reports about the company. Chardan Capital dropped their price target on Tenaya Therapeutics from $18.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday. HC Wainwright dropped their price target on Tenaya Therapeutics from $18.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday. Morgan Stanley dropped their price target on Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Canaccord Genuity Group lowered their target price on Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating on the stock in a research report on Thursday. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $6.25.

Tenaya Therapeutics Trading Up 4.3 %

TNYA stock opened at $0.70 on Thursday. The business’s 50-day moving average price is $1.06 and its two-hundred day moving average price is $1.82. Tenaya Therapeutics has a 1-year low of $0.39 and a 1-year high of $5.39. The firm has a market cap of $55.37 million, a PE ratio of -0.49 and a beta of 2.83.

Hedge Funds Weigh In On Tenaya Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Woodline Partners LP bought a new stake in shares of Tenaya Therapeutics during the fourth quarter worth approximately $28,000. Trustees of Columbia University in the City of New York acquired a new position in Tenaya Therapeutics during the fourth quarter valued at approximately $417,000. Nuveen Asset Management LLC raised its position in Tenaya Therapeutics by 25.2% during the fourth quarter. Nuveen Asset Management LLC now owns 345,192 shares of the company’s stock valued at $494,000 after purchasing an additional 69,377 shares in the last quarter. Ground Swell Capital LLC acquired a new position in Tenaya Therapeutics during the fourth quarter valued at approximately $32,000. Finally, Deutsche Bank AG increased its holdings in shares of Tenaya Therapeutics by 304.1% during the fourth quarter. Deutsche Bank AG now owns 129,319 shares of the company’s stock worth $185,000 after buying an additional 97,318 shares in the last quarter. Institutional investors own 90.54% of the company’s stock.

Insider Buying and Selling

In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III purchased 35,714,284 shares of Tenaya Therapeutics stock in a transaction that occurred on Wednesday, March 5th. The stock was acquired at an average price of $0.70 per share, for a total transaction of $24,999,998.80. Following the completion of the acquisition, the insider now owns 49,313,559 shares of the company’s stock, valued at approximately $34,519,491.30. This trade represents a 262.62 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 19,621 shares of company stock worth $10,595. Company insiders own 32.76% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.